Alcoholic & MASLD liver disease — spectrum, Maddrey, Lille and resmetirom viva

Interpretation

The examiner opens: "A 45-year-old man who drinks heavily presents with jaundice, an AST of 195 and ALT of 70. Talk me through the spectrum of fatty liver disease, how you grade his severity, and what you do about it. Then contrast that with the management of the patient with metabolic fatty liver disease."

• The two diseases — alcohol-related liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD) — share a single histological pathway: steatosis to steatohepatitis to fibrosis to cirrhosis to hepatocellular carcinoma, but enter it by different insults: alcohol (ethanol and its toxic metabolite acetaldehyde) versus metabolic dysfunction (insulin resistance, lipotoxicity).^[1][10]

Key points

The examiner will probe each of these; be ready to defend them at viva depth:

1. The 2023 nomenclature change (Rinella, Journal of Hepatology 2023). NAFLD became MASLD (metabolic dysfunction-associated steatotic liver disease); NASH became MASH; and a new MetALD category captures patients in whom alcohol and metabolic disease both contribute substantially. The diagnosis of MASLD requires hepatic steatosis plus at least one metabolic criterion (overweight/obesity, type 2 diabetes, or metabolic dysregulation). The change removes the stigma of 'fatty' and anchors the diagnosis to metabolic dysfunction rather than the absence of alcohol.^[2]

2. The alcoholic hepatitis biochemistry pattern. AST greater than ALT (ratio over 2), both under 300 U/L, with disproportionately high GGT, macrocytosis (MCV over 100 fL) and a bilirubin high out of proportion to the modest transaminitis. In MASLD the ratio is under 1 (ALT predominant). The ratio reverses to over 1 in any advanced cirrhosis, so it is unreliable in end-stage disease.^[1]

3. The molecular mechanism — ethanol metabolism. ADH converts ethanol to acetaldehyde; ALDH2 converts acetaldehyde to acetate; CYP2E1 (induced in chronic drinkers) and catalase are minor routes. The high NADH:NAD+ ratio blocks fatty-acid beta-oxidation and drives triglyceride synthesis (steatosis). Acetaldehyde-protein adducts and ROS injure hepatocytes; gut-derived LPS activates Kupffer cells via TLR4 to release TNF-alpha, IL-1, IL-6, TGF-beta. TGF-beta and PDGF activate hepatic stellate cells (the Ito cell) into alpha-SMA-positive myofibroblasts that lay down collagen I/III — the structural basis of fibrosis and cirrhosis.^[1]

4. Maddrey Discriminant Function reproduced verbatim. Maddrey DF = 4.6 x (patient PT − control PT in seconds) + total bilirubin (mg/dL). A value of 32 or more = severe alcoholic hepatitis — the threshold to consider corticosteroids after excluding infection and GI bleed.^[5]

5. Corticosteroids and the STOPAH evidence. For severe AH: prednisolone 40 mg PO daily for 28 days then taper (or methylprednisolone 32 mg IV). The STOPAH trial (Thursz, NEJM 2015) showed prednisolone improves 28-day mortality in responders but no benefit at 90 days or 1 year; pentoxifylline had no benefit. Assess response at day 7 with the Lille score (Louvet 2007): over 0.45 = non-responder, corticosteroids are futile (6-month mortality about 75 percent), discontinue and consider early transplant. Many units add N-acetylcysteine as an adjunct.^[3][4]

6. The resuscitation bundle for severe AH. ABCDE; exclude and treat sepsis and GI bleed before corticosteroids (cultures, ascitic tap, endoscopy); thiamine BEFORE glucose to prevent Wernicke; correct glucose, K+, Mg2+, PO4 (refeeding); symptom-triggered chlordiazepoxide for withdrawal (lorazepam in liver failure); enteral high-protein feeding (35 kcal/kg/day, 1.2–1.5 g/kg/day protein).^[1]

7. MASLD management — the dose-response for weight loss. 3–5 percent reduces steatosis; 7–10 percent resolves MASH; over 10 percent regresses fibrosis. Foundation is a Mediterranean diet, 150 min/week aerobic plus resistance exercise, and alcohol avoidance. Treat diabetes and lipids; statins are safe and should not be withheld.^[2]

8. MASLD pharmacotherapy for F2–F3 MASH. Resmetirom (80 mg PO daily, uptitrated to 100 mg) — a thyroid hormone receptor-beta agonist, the first FDA-approved MASH drug (2024); MAESTRO-NASH (Harrison, NEJM 2024) showed MASH resolution and fibrosis improvement. Pioglitazone (30–45 mg daily) — PPAR-gamma agonist, best in T2DM (PIVENS, Sanyal 2010); weight gain, fluid retention, fracture risk. GLP-1 agonists (semaglutide, tirzepatide) — attractive with obesity/T2DM. Vitamin E (800 IU/day) — histological benefit in non-diabetic MASH; controversial long-term.^[6][9]

9. HCC surveillance. Both diseases, once cirrhotic, need 6-monthly ultrasound (plus alpha-fetoprotein). Uniquely, MASLD can cause HCC even without cirrhosis — surveillance of the non-cirrhotic high-risk patient is an evolving controversy.

10. The two highest-yield one-liners. "AST-over-ALT-over-2, both under 300, high MCV = alcoholic hepatitis; Maddrey 32 or more = steroids; Lille over 0.45 at day 7 = stop." And: "Weight loss 7–10 percent resolves MASH; resmetirom is the first MASH drug (2024); both need HCC surveillance once cirrhotic."

References

1. O'Shea RS, et al. Alcoholic liver disease. American Journal of Gastroenterology 2010.^[1]
2. Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology 2023.^[2]
3. Thursz MR, et al. Prednisolone or pentoxifylline for alcoholic hepatitis (STOPAH). New England Journal of Medicine 2015.^[3]
4. Louvet A, et al. The Lille model. Hepatology 2007.^[4]
5. Maddrey WC, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978.^[5]
6. Harrison SA, et al. Resmetirom in NASH with fibrosis (MAESTRO-NASH). New England Journal of Medicine 2024.^[6]

References8ShowHide

1. [1]O'Shea RS, Dasarathy S, McCullough AJ, et al. Alcoholic liver disease. American Journal of Gastroenterology, 2010.PMID 19904248
2. [2]Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology, 2023.PMID 37364790
3. [3]Thursz MR, Forrest EH, Ryder S Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine, 2015.PMID 26176387
4. [4]Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis with steroids. Hepatology, 2007.PMID 17518367
5. [5]Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology, 1978.PMID 352788
6. [6]Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. New England Journal of Medicine, 2024.PMID 38324483
7. [9]Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS). New England Journal of Medicine, 2010.PMID 20427778
8. [10]Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology, 2016.PMID 26928243